An update from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group has announced that its innovative antidepressant, Ruoxinlin®, has been approved for marketing in Macao. This drug, which is China’s first independently developed Class 1 innovative chemical drug for MDD, has shown significant efficacy in reducing symptoms like anxiety and fatigue without adverse side effects. Since its launch in mainland China in 2022, Ruoxinlin® has gained clinical recognition and was recently included in China’s National Reimbursement Drug List, enhancing its accessibility and potential market impact.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company that focuses on the development and marketing of innovative drugs. It operates primarily in the field of mental health, with a particular emphasis on treatments for major depressive disorder (MDD) and other related conditions.
YTD Price Performance: -5.90%
Average Trading Volume: 100
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.01B
See more insights into 2186 stock on TipRanks’ Stock Analysis page.